(RTTNews) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to $400 million.
"TREX1 has demonstrated significant potential in the pre-clinical phase, and our decision to sell the program, rather than license it, reflects a strategic shift toward more flexible, value-driven exit opportunities," said Johan Emilsson, CEO of Sprint Bioscience.
Sprint Bioscience is based in Stockholm with operations located in Huddinge.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
